Related Experiment Video

Updated: Jul 15, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs

Andrew Wagner1

  • 1Harvard Medical School, Department of Medical Oncology and Ludwig Center for Cancer Research, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. awagner@partners.org

Journal of the National Comprehensive Cancer Network : JNCCN
|April 20, 2007
PubMed

Insights

Advanced soft tissue sarcomas are difficult to treat with conventional chemotherapy. Novel molecularly targeted therapies offer more specific and effective treatment options for sarcomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Conventional chemotherapy has shown limited efficacy in treating advanced soft tissue sarcomas for over three decades.
  • Dose and combination modifications of existing chemotherapies have not yielded substantial improvements in response rates or overall survival.

Purpose of the Study:

  • To review the challenges in treating advanced soft tissue sarcomas.
  • To highlight the impact of novel molecularly targeted therapies in sarcoma treatment.
  • To discuss the future of personalized medicine in sarcoma therapy.

Main Methods:

  • Literature review of clinical trials and therapeutic advancements in soft tissue sarcoma treatment.
  • Analysis of the impact of targeted therapies, using imatinib for gastrointestinal stromal tumors as an example.
  • Discussion of emerging research on genetic mechanisms and targeted agents.

Main Results:

  • Conventional chemotherapy offers modest efficacy, with limited survival benefits.
  • Targeted therapies, like imatinib, have revolutionized sarcoma treatment by inhibiting specific molecular alterations.
  • Identification of underlying genetic mechanisms is crucial for developing new, effective therapies.

Conclusions:

  • Novel therapies targeting specific molecular alterations represent a paradigm shift in sarcoma treatment.
  • Future research focusing on genetic mechanisms will lead to more precise, less toxic, and highly effective sarcoma therapies.
  • Personalized medicine approaches hold significant promise for improving outcomes in soft tissue sarcoma patients.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...